Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215666 | 1.00 | ADRA2C (0.34) | ADRA2CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17217533 | 0.88 | NPC1 (0.39) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL17217530 | 0.88 | NPC1 (0.39) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL17216461 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL17216460 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL17219001 | 0.85 | LMNA (0.32) | KMT2AGAA | |
| SCHEMBL17219003 | 0.85 | LMNA (0.32) | KMT2AGAA | |
| SCHEMBL17218205 | 0.85 | ALDH1A1 (0.33) | MEN1KMT2A | |
| SCHEMBL17219403 | 0.85 | TP53 (0.34) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17216678 | 0.85 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940012-B1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9560850-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2940012-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | Sumitomo Chemical Company Limited (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | RTN3, CYP51A1, TCOF1 | ADRA2C 2647/4885NPC1 1841/4885RAB9A 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.